EUCTR2015-003196-29-IT进行中（未招募）1 期
A Registry Study to Evaluate the Survival and Long-Term Safety of SubjectsWho Previously Received Talimogene Laherparepvec in Amgen or BioVEXSponsoredClinical Trials - NA
AMGEN INC.0 个研究点目标入组 200 人开始时间: 2021年6月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. All subjects must provide informed consent prior to initiation of any
- •study activities. When the subject is legally too young to provide
- •informed consent/assent, subject's legally acceptable representative
- •must provide informed consent/assent based on local regulations
- •and/or guidelines prior to initiation of any study activities
- •2. All subjects must have received at least one dose of talimogene
- •laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any
- •tumor type and must have discontinued treatment and participation,
- •including long-term follow-up (if applicable) in that trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 140
排除标准
- •1. Subjects currently receiving talimogene laherparepvec in Amgen or
- •BioVEX-sponsored clinical trial
- •2. Subject currently participating, including for long-term follow-up (if
- •applicable), in other Amgen-sponsored talimogene laherparepvec clinical
研究者
相似试验
进行中（未招募）
1 期
A Registry study to evaluate the survival and long-term safety of subjects who have received at least one dose of talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial.Any tumor type eligible for treatment with talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trialEUCTR2015-003196-29-GBAmgen Inc.200
进行中（未招募）
1 期
A Registry study to evaluate the survival and long-term safety of subjects who have received at least one dose of talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial.Any tumor type eligible for treatment with talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trialEUCTR2015-003196-29-ESAmgen Inc.200
进行中（未招募）
1 期
A Registry study to evaluate the survival and long-term safety of subjects who have received at least one dose of talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial.Any tumor type eligible for treatment with talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trialMedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2015-003196-29-DEAmgen Inc.200
尚未招募
不适用
Retrospective analyze of survival rate, complications and quality of live after use of an Extracorporeal Life Support System (ECLS)All Patients who received ECLS are included no matter which health condition they had before. But mostly they had a heart attack or a cardiogenic shock or similar.DRKS00015685niversitätsklinikum Freiburg400
进行中（未招募）
1 期
A Non-Interventional Study to Monitor the Survival Status ofPatients that Discontinued from ISIS 420915-CS2 orISIS 420915-CS3Familial Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2017-005115-13-PTIonis Pharmaceuticals, Inc.164